Hageal cancer. Anticancer Res 2011;31(2):63338 9. Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil mixture chemotherapy in individuals with advanced or recurrent squamous cell carcinoma in the esophagus. Oncology 2011;80(5):30713 ten. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705715 11. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17): 1695704 12. Tanaka Y, Yoshida K, Sanada Y, Osada S, Yamaguchi K, Takahashi T. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for sophisticated esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol 2010;66(6):1159165 13. Nakajima M, Kato H. Remedy choices for esophageal squamous cell carcinoma. Specialist Opin Pharmacother 2013; 14(10):1345354 14. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277(5698):66567 15. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities employing paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003;104(1):12129 16. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I et al. A phase II study of single-agent docetaxel in sufferers with metastatic esophageal cancer. Ann Oncol 2004;15(6):955AcknowledgmentsThe authors declare that they’ve no conflict of interest.
Pasco et al. BMC Obesity 2014, 1:9 http://www.biomedcentral.com/2052-9538/1/RESEARCH ARTICLEOpen AccessBody mass index and measures of physique fat for defining obesity and underweight: a cross-sectional, population-based studyJulie A Pasco1,2*, Kara L Holloway1, Amelia G Dobbins1, Mark A Kotowicz1,two, Lana J Williams1 and Sharon L Brennan1,AbstractBackground: The body mass index (BMI) is frequently employed as a surrogate marker for adiposity.1346270-08-3 Order Even so, the BMI indicates weight-for-height devoid of thinking about differences in body composition and also the contribution of body fat to all round physique weight.Oxetane-2-carboxylic acid uses The aim of this cross-sectional study was to recognize sex-and-age-specific values for percentage physique fat ( BF), measured making use of whole physique dual energy x-ray absorptiometry (DXA), that correspond to BMI 18.PMID:24189672 5 kg/m2 (threshold for underweight), 25.0 kg/m2 (overweight) and 30.0 kg/m2 (obesity) and compare the prevalence of underweight, overweight and obesity in the adult white Australian population working with these BMI thresholds and equivalent values for BF. These analyses utilise information from randomly-selected males (n = 1446) and ladies (n = 1045), age 206 years, who had concurrent anthropometry and DXA assessments as a part of the Geelong Osteoporosis Study, 2001008. Outcomes: Values for BF cut-points for underweight, overweight and obesity have been predicted from sex, age and BMI. Using these cut-points, the age-standardised prevalence among males for underweight was 3.1 (95 CI 2.1, four.1), overweight 40.four (95 CI 37.7, 43.1) and obesity 24.7 (95 CI 22.2, 27.1); amongst females, prevalence for underweight was 3.eight (95 CI 2.6, 5.0), overweight 32.3 (95 CI 29.5, 35.two) and obesity 29.five (95 CI 26.7, 32.3). Prevalence estimates applying BMI criteria for men were: underweight 0.six (95 CI 0.two, 1.1), overweight 45.5 (95 CI 42.7, 48.2) and obesity 19.7 (95 C.